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Human malignant melanoma is a common primary malignant cutaneous tumour derived from transformed
epidermal melanocytes. Patients with melanoma have a high rate of mortality due to resistance to
chemotherapeutic drugs, a major obstacle to a successful treatment. Several reports have suggested that CD146
plays an important role as a signalling molecule in human melanoma. This role includes CD146 as a participant in
inflammation, differentiation, adhesion, tumourigenicity, metastasis, invasion and angiogenesis among other
processes, which suggests that this molecule promotes the progression of human melanoma as a multifaceted
regulator. In this article, we explore the effects and corresponding mechanisms with respect to the role of CD146/
MUC18 in the promotion of human melanoma progression. Collectively, the studies indicated that targeting CD146,
because it is a suitable marker of poor patient outcome, might be useful in the design of future strategies for the
prevention and treatment of human melanoma.
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in the past several decades, the incidence of melanoma
has continued to grow, especially among males, whites,
patients older than 60 years, and persons of lower socio-
economic status in the United States and in many other
countries [1,2]. As the deadliest form of skin malignancy,
this tumour type can metastasise to virtually any organ,
even years after resection of the primary lesion. Less
than one-third of the survivors of melanoma (32%) are
in an older age group, and this group suffers most from
the burden of the disease and its associated mortality
[3]. Despite new treatments that have emerged in recent
years that are based on the principle of adjuvant chemo-
therapy, such as immunotherapy and gene therapy, sur-
vival rates for melanoma patients remain disappointing.
In this review, we focus mainly on the role of CD146 in
the progression of melanoma, and also propose that the
targeting of CD146 may be useful in the design of future
strategies for the prevention and treatment of human
melanoma.* Correspondence: LX6990064@126.com
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unless otherwise stated.CD146, a recently identified integral member of the
cell adhesion molecule (CAM) family [4], is also referred
to as MUC18 or MCAM. This protein is frequently over
expressed on the surface of advanced and metastatic
human melanoma cells; however, its expression is rare in
benign nevi [5,6]. Studies in which CD146 is overex-
pressed have shown that the molecule plays an important
role in promoting the progression of metastatic melano-
mas and is directly associated with poor patient prognosis
[7,8]. Thus, CD146 has been identified as a marker of the
progression of melanoma [9].Structure of human CD146 (huCD146)
HuCD146 is a glycoprotein with a typical single-spanning
transmembrane structure (Figure 1A). HuCD146 is com-
posed of either 646 or 603AA, including an N-terminal
extracellular domain of 558 AA, a transmembrane domain
of 24 AA (559–582), a long C-terminal cytoplasmic do-
main of 64 AA and a short cytoplasmic domain of 21 AA.
The extracellular portion of huCD146 has five disulphide-
bonded domains (V-V-C2-C2-C2) that contain eight
potential N-glycosylation sites (Asn-Xaa-Ser/Thr)
(Figure 1A). The eight potential N-glycosylation sites are
located at positions 56, 418, 449, 467, 508, 518, 527s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The putative structure of huCD146 protein and mechanisms that CD146 regulates the survival of melanoma. A. The putative
structure of huCD146 protein. The CD146 sequence has three conserved motifs: a KKGK motif, a PKC site and a C terminus. The anti-CD146 mAbs
that recognise the cognate epitopes in the extracellular domain are shown in the schematic diagram. B. CD146 is involved in both inside-out and
outside-in signalling. Activation of the PI3K–AKT pathway can up-regulate the cell surface expression of CD146 (inside-out), and the cell surface
expression of CD146 can in turn activate the PI3K–AKT pathway (outside-in).
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glycosylation sites are conserved between the human and
mouse CD146 proteins, which suggests that their function
is very important. Similar to chicken, rat, and mouse
gicerin, huCD146 contains two isoforms that are gener-
ated by alternative splicing and that differ in their cyto-
plasmic domain; CD146-s has a short cytoplasmic domain
whereas CD146-l has a long cytoplasmic domain [14]
(Figure 1A). Contained within these segments are several
protein kinase recognition motifs that can potentially
be phosphorylated by protein kinase A (PKA) or protein
kinase C (PKC) [14] (Figure 1A). In addition to the
membrane-anchored form, CD146 also exists in a soluble
form (sCD146) that is generated by the ectodomain
shedding of membrane CD146 (mCD146) in a calcium-
induced, matrix metalloproteinase (MMP)-dependent
manner [15]. Its protein structure suggests that huCD146
can perform the typical functions of CAMs, such as the
mediation of cross-talk with growth factor receptors and
intracellular signalling pathways and the promotion of
intracellular interactions with the cytoskeleton; these
functions can also affect tumour progression and patient
prognosis [16].Location of huCD146 expression in the subcellular
structures of human melanoma cells
Using anti-CD146 monoclonal antibodies (mAbs) for im-
munofluorescence staining and for surface radioiodination
of melanoma cell lines, Witze et al. [17] demonstrated the
presence of CD146 on the cellular membrane. This work
was supported by more studies with the anti-CD146
mAbs, AA1 and AA2, which helped determine that
CD146 is localized to the surface of A375 cells [11]. Al-
though CD146 is predominantly expressed on the sur-
face of melanoma cells, it has also been found to be
expressed in the cytoplasm and at the cell-cell junctions
between adjacent cells, but not in the nuclei of most
human melanoma cells [10,17]. The latter report was
consistent with studies identifying huCD146 expression
on epithelial ovarian cancer and prostate cancer cells
[10,18]. This finding indicates that the CD146 expres-
sion pattern might be common and conserved in human
tumour cells. However, the treatment of melanoma cells
with Wnt5a led to a redistribution of CD146 into a
polarised structure at the tail end of the cells; further
assembly occurred between actin and myosin II with
CD146 to form the Wnt5a-mediated receptor –actin –
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polarised CD146 at the tail-end of cells was also demon-
strated in HUVEC, C2C12 myoblast cells, HT1080
fibrosarcoma, and adult hippocampal progenitor cells.
During cytokinesis of cells, CD146 was enriched within
the contractile ring; and remained pinned on the rear of
each migrating daughter cell at the site of abscission
[21]. The location of CD146 expression in subcellular
structures might facilitate the homotypic adhesion, mo-
tility and invasiveness of human melanoma cells.
CD146 plays a positive role in promoting the
progression of inflammation
The most recent reports showed that inflammation can
promote melanoma progression through a variety of
mechanism, such as through tumour initiation, angiogen-
esis and metastasis [22,23]. Recently, increased CD146 ex-
pression was reported in inflammatory lesions compared
with normal cells. For example, strong staining for CD146
was revealed during the initial inflammatory response in
inflammatory bowel disease and in a model of pulp expos-
ure [24,25]. Coincidentally, CD146+ mesenchymal cells
were significantly overrepresented in the intimal layer
of inflamed spondylarthritis synovium [26]; in addition,
CD146+ alveolar macrophages were overrepresented in
the lungs of patients with COPD and asthma [27]. More-
over, elimination of CD146 can significantly ameliorate
the severity of inflammation, in murine models of colitis
[24], as well as in experimental autoimmune encephalo-
myelitis [28]; Suppression of CD146 can also decreased
the tumour incidence and tumour progression in a murine
model of colitis-associated colorectal carcinogenesis [24].
However, the way in which CD146 regulates the progres-
sion of inflammation is not yet known.
Mechanistic studies have shown that inflammatory
cytokines, such as tumour necrosis factor-alpha (TNF-α)
up-regulate the expression of endothelial CD146 through
the transactivation of NF-κB [24,25] (Table 1). In turn,Table 1 CD146-correlated signals and brief mechanisms that
Signalling pathway Progression Mechanism
TNF-α-NF-κB-CD146 CD146-NF-κB inflammation promotion proinflam
CD146-PI3K–AKT-CD146 survival inhibition of the pro
staurosporine-induce
PAR1-PAFR-CD146 metastasis promotion of hetero
of the ability for me









CD146-NF-κB p50-IL-6-VEGF angiogenesis Promotion of endot
of capillary-like strucincreased CD146 expression promotes proinflammatory
extravasations of leukocyte, in part through enhancing
the activation of NF-κB [27] (Table 1). Both blockade of
CD146 and depletion of CD146 (+) CD4 (+) T lympho-
cytes restrict the migration of T(H)17 lymphocytes
across the blood–brain barrier of endothelial cells. This
depends on the targeting of CD146 to the endothelium,
but not to lymphocytes [28,29]. In addition, the latest
report showed that inflammation promotes the progres-
sion of melanoma [30]. These results indicate that CD146
could serve as a potential biomarker for inflammation and
represents a valuable target for the treatment of inflamma-
tory diseases, and, further, could affect the progression of
melanoma via the regulation of the extent inflammation.
CD146 enhances the stem cell phenotype
It was believed that the self-renewing capacity and mul-
tipotency of melanoma cells depended on the ability to
switch phenotypes, which implied that the tumour had
the potential to adopt a stem cell-like phenotype [31].
The higher the degree of malignancy, the more obvious
the stem cells properties become. CD146 expression is
closely related to phenotype and to the differentiation
of stem cells. Compared with parental and lineage-
committed mesenchymal stem cells (MSCs), the following
MSCs with stem cell properties exhibited a greater in-
crease in CD146 expression: multipotent cells isolated
from heterogeneous MSC cultures, rapidly dividing cells
obtained via fluorescence-activated cell sorting, and
placenta-derived MSCs [32,33]. After several passages
and during aging and differentiation, CD146 was down-
regulated [34]. Moreover, CD146 knockdown in MSCs
could impair the proliferation and the potential for dif-
ferentiation into an adipogenic lineage [33]. These data
suggested that CD146 probably enhanced the stem cell
phenotype and was a maker of embryonic development/
stem cells. This notion was supported by the observa-
tion that in transitions from normal skin to melanoma,influence melanoma progression
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the enhanced stem cell-like ability of colony formation
and differentiation [35]. In the process of transendo-
thelial migration of melanoma cells, the interaction be-
tween melanoma cells and the vascular surface induces
the differential expression of genes linked to cancer migra-
tion and embryonic/ stem cell properties [36]. In addition,
CD146 can be utilised in the prospective enrichment for
stem cells. For instance, muscle side population cells,
known as tissue-specific stem cells of skeletal muscle,
have already been successfully purified from human
fetal muscle based on CD146 expression as detected
by fluorescence-activated cell sorting in conjunction
with the expression of robust myogenic cell surface
markers [37,38].
The effect of CD146 on the tumourigenicity of
human melanoma in vivo and tumour cell growth
in vitro
A recent study demonstrated that huCD146 increases the
tumourigenicity of human melanoma cells in nude mice
[39]. This work was supported by other reports that found
that treatment with an anti-CD146 mAb (ABX-MA1) or
the silencing of CD146-s inhibited melanoma growth
in vivo in nude mice [40,41]. However, in severe combined
immunodeficiency (SCID) mice, CD146 expression min-
imally affected the tumourigenicity of melanoma cells, as
CD146 transfection into both human melanoma SK-2 and
XP44RO(Mel) cell lines (which are normally CD146-
negative) resulted in tumour formation comparable to, or
even smaller, than their respective vector controls in SCID
mice [42]. However, the results were different when breast
cancer cells were used; in this case, CD146 expression
increased the tumourigenicity equally in both nude and
SCID mice [43,44].
To further investigate the role of the CD146 in the
tumourigenicity of human melanoma cells under more
clinically relevant conditions, Wu et al. [5] used a syn-
geneic C3H mouse model with a complete immune sys-
tem. They determined that the ectopic expression of
CD146 in the two CD146-negative, low-metastatic
mouse melanoma K1735 sublines (K1735-3 and K1735-
10) was not associated with their tumourigenicity,
which suggested that the immune system might partici-
pate in the regulation of CD146-mediation of tumour
growth in vivo.
However, studies on the effects of CD146 on the
growth of melanoma cells in vitro and in vivo still
needed to be performed. Todorovic [45] and Zigler [41]
found that CD146 did not affect melanoma cell prolifera-
tion in vitro, regardless of whether the cells were treated
with ABX-MA1 or were CD146-silenced. These results
contrasted sharply with the results from the in vivo nude
mouse model.Li et al. suggested a molecular and biochemical
explanation for the above results [46] (Figure 1B, Table 1).
It has been shown that AKT, a critical regulator of PI3K-
mediated cell survival, is constitutively activated in melan-
oma cell lines (isolated from clinically and histologically
defined lesions) and in tumour samples, which excluded
the possibility that the constitutively phosphorylated AKT
observed in the cell lines was a cell culture artefact. These
results indicate that tissue culture cells do not activate the
AKT survival pathway, a finding that has also been ob-
served in prostate cancer cells [47]. These data are also
supported by recent studies demonstrating that AKT acti-
vation is not altered in CD146 small interfering (si)RNA-
and/or antisense-transfected tissue culture melanoma cells
[48]. Li’s study found that CD146 and AKT were recipro-
cally regulated in vivo; CD146 was activated by the PI3K–
AKT pathway, and the expression of CD146 in melanoma
cells positively regulated AKT. Thus, a circular signalling
network was identified (Figure 1B). In vivo the increased
survival of CD146-transduced melanoma cells was dem-
onstrated by the cellular inhibition of the pro-apoptotic
protein BAD, the cellular resistance to staurosporine-
induced cell death, and the cleavage of caspase 3, an early
event during apoptosis [46]. Collectively, these studies
indicated that the increase in in vivo tumourigenesis by
the enforced expression of huCD146 in melanoma cells
enhanced the survival of the cells by promoting phospho-
AKT and inactivating BAD in the tumours. Therefore,
intervenion in the CD146-AKT pathway in melanoma
may be a valid therapeutic approach. The CD146-AKT
interaction might also explain why CD146 did not affect
cell proliferation in vitro, as cultured melanoma cells did
not activate the PI3K-AKT pathway.
Intriguingly, the reciprocal regulation between CD146
and AKT might also occur in prostate cancer cells [47],
or in normal cells, such as HUVECs, no matter in vivo
or in vitro [49,50]. Currently, no direct evidence has
been reported with regard to the interaction of CD146
with AKT in other tumour types, including human leu-
kaemia, cervical carcinoma, hepatocellular carcinoma or
ovarian carcinoma [51]. Confirmation of this interaction
in other cell types will require significant additional work.
CD146 contributes to increased lung metastasis
(via intravenous injection) and adhesion of
human melanoma cells
Metastasis, which involves the dissemination of malig-
nant cells from a primary tumour to regional lymph
nodes and distant organs, is a complex process that has
been at the centre of cancer research for decades. Previous
studies have shown that CD146 expression in melanoma
cells directly correlates with the ability of the cells to
metastasies in in vivo mouse models [5,39,52]. However,
according to Leslie et al. [53], expression of CD146 might
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vation was supported by a recent study demonstrating
significantly reduced lung metastases in nude mice
injected with CD146-silenced A375SM and C8161 cells
compared with mice injected with control -transduced
cells [41].
In contrast to the results of the spontaneous metasta-
sis assays, these above reports have also shown that
other CD146-expressing melanoma cells, such as SK-2
do not lead to lung metastases even though the expres-
sion levels are similar to transfected XP44RO(Mel) [42].
Similarly, CD146-transfected K1735-10 clones showed
only microscopic lung modules in 86% of the mice com-
pared with numerous large lung nodules induced by
transfection of K1735-3 in all of the mice [5]. Two pos-
sible explanations for these findings are as follows: (1)
CD146 expression alone might not be sufficient to cause
in vivo metastasis [54]. Some upstream and downstream
cofactors, such as c-KIT, IL-8, and AP-2, are present in
different amounts, which might modulate the effect of
CD146 on metastasis [55]; (2) Metastasis may be affected
by the various intrinsic properties of different CD146-
expressing sublines/cell lines [39]. In addition, CD146
mediated the metastasis of melanoma cells by impacting
on only the later stages of metastasis, namely, extravasa-
tion and the establishment of new foci of growth [56]. In
contrast, CD146 expression in human prostate cancer
exerts an influence on multiple steps in the metastatic
process, not only at the later stages [57].Figure 2 The signalling pathways show that CD146 regulates the me
PAR1-PAFR-CD146 signalling axis in human melanoma cells is shown. PAR1
of CREB and to recruit CREB and Sp1 to the promoter of CD146, which trig
to the acquisition of an invasive phenotype of melanoma. CD146 regulates th
in turn, results in increased binding of both Ets-1 and Sp1 to the MMP-2 promCD146 also plays a role in cell adhesion in vitro,
including the promotion of heterotypic (melanoma-endo-
thelium) and homotypic adhesion (melanoma-melanoma)
[40,58]. In the absence of a direct role in tumour-
endothelial adhesion in vivo, a CD146-mediated homoty-
pic aggregation between metastatic melanoma cells might
be important in extravasation; indeed, as tumour cell clus-
ters (embolus formations) are more likely to become
trapped within the capillary beds and lymphatic vessels,
they may easily survive and establish new foci within the
vascular system [59]. This phenomenon might partially
explain why CD146 only affected the later stages of the
metastatic process in melanoma cells. As early steps in the
metastatic process require a reduction in homotypic adhe-
sion, which allowed the cells to detach from the primary
tumour, homotypic aggregation mediated by CD146 might
play a secondary role at this stage [35].
To further investigate the molecular mechanism of
the CD146-mediated metastasis and adhesion of human
melanoma cells (heterotypic adhesion), Melnikova and
colleagues [60] used lentiviral deliver of shRNA or
siRNA to stably silence protease-activated receptor 1
(PAR1), platelet-activating factor receptor (PAFR), or
CD146 expression in human melanoma C8161-c9 cells.
The results demonstrated a reduction in the attach-
ment of the cells to the human dermal microvascular
endothelial cells (HDMECs) and the inhibition of melan-
oma metastasis after an injection of melanoma cells into
the tail-vein of mice (Figure 2A). The silencing of PAR1,tastasis and invasion of melanoma. A. A presumed model for the
works in concert with PAFR to activate PAFR-induced phosphorylation
gers CD146 expression in metastatic melanoma. B. CD146 contributes
e expression of Id-1 and binds to the Id-1 promoter. Id-1 overexpression,
oter and further promotes MMP-2 expression.
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oma cells to migrate through HDMEC monolayers (diape-
desis), an essential step in the metastatic cascade. This
was partly due to the decreased ability of the cells to form
heterotypic adhesions [61]. Overall, PAR1, PAFR, and
CD146 play a critical role in the heterotypic adhesion, the
retention of the ability to metastasise, and the diapedesis
of melanoma cells. Previous studies in mice also showed
that PAR1-silenced melanoma cells with a low metastatic
potential became highly metastatic upon transfection with
PAR1 [62], which suggested that PAR1 expression was
directly correlated with tumour metastasis in melanoma.
It is notable that CD146 overexpression only partly res-
cued PAR1 functions (heterotypic adhesion and metasta-
sis), whereas PAFR overexpression could fully rescue
PAR1 functions in PAR1-silenced cells. Melnikova et al.
indicated that in the absence of PAR1 function, CD146
was necessary, but not sufficient to promote a metastatic
phenotype in cases of melanoma. CD146 acted as a rate-
limiting factor in heterotypic adhesion interactions with
other PAFR downstream molecules that resulted in the
diapedesis and metastasis of melanoma cells. PAFR played
a critical role in the stimulation of PAR1-induced me-
tastasis (Figure 2A). Together, the PAR1-PAFR-CD146
pathway mediated heterotypic adhesion, diapedesis, and
metastatic retention of melanoma cell in the lungs. There-
fore, the PAR1-PAFR-CD146 axis is an attractive target
for the prevention of metastatic melanoma (Table 1). In
addition, with the exception of PAR1 and PAFR, moesin,
but not ezrin, was also necessary for the metastasis of
melanoma to the lungs; this protein, both physically in-
teracts with and was recruited by CD146 [13,54].
CD146 expression significantly increases the
invasion and motility of human melanoma cells
in vitro
The positive effects of CD146 expression on the motility
and invasiveness of human melanoma cell lines in vitro,
as described by Wang et al. [58], were due to the increased
activity of MMPs and WRAMP as stimulated by CD146-
expressing cells [20]. These augmented biological charac-
teristics could be reversed using anti-CD146 mAbs; or by
the silencing of CD146 [19,41]. MMPs, a family of zinc-
dependent endopeptidases, have been shown to have key
roles in tumour cell invasion, metastasis, and angiogenesis
via the degradation of the extracellular matrix.
To understand how CD146 regulates the expression
and activity of MMPs, Zigler et al. [41] demonstrated that
reduced CD146 expression down-regulated the expression
of the inhibitor of DNA binding-1 (Id-1) protein and en-
hanced the expression of activating transcription factor
3 (ATF-3). When the expression of CD146 was rescued
in CD146–knockdown melanoma cells, Id-1 expression
was increased, and ATF-3 expression was reduced, whichshowed that both Id-1 and ATF-3 were specifically reg-
ulated by CD146 [41]. Id-1 is a regulator of gene tran-
scription, and it formed a heterodimer with basic
helix-loop-helix (bHLH) transcription factors and in-
hibits their transactivation function. ATF-3 is a member
of the ATF/CREB family of transcription factors that was
found to be induced by the p38 MAPK signalling pathway
and to negatively regulate Id-1 expression [41,63]. This
observation was consistent with the finding that the
levels of phosphorylated MAPK were slightly decreased
in CD146-transduced melanoma cell lines [46]. One study
demonstrated that Id-1 positively regulated MMP-2 tran-
scription by affecting both the expression and binding of
the Ets-1 and Sp1 transcription factors to the MMP-2
promoter (excluding AP-2, p53, and CREB, although
these transcription factors could modulate MMP-2
expression). It has also been shown that CD146 contrib-
utes to human melanoma cell invasion through the
regulation of MMP-2 transcription and protein expres-
sion via Id-1 [41]. The latter study concluded that CD146
increased the expression of Id-1 via the down-regulation
of ATF-3 expression, which induced the positive regula-
tion of MMP-2 expression and activity and the promotion
of melanoma cell invasion (Figure 2B, Table 1).
Although the mechanism of cellular invasion has been
demonstrated for endothelial cells, such as HUVECs and
endothelial cells harvested from the lungs of IKKβflox/
flox mice [49,50,64], few real studies have been con-
ducted that have elucidated the motility mechanism of
human melanoma cells. In an effort to determine the
exact molecular mechanism of CD146-stimulated migra-
tion of human melanoma cells, a recent study found that
CD146 physically interacts with phosphorylated ezrin–
radixin–moesin (p-ERM) proteins and recruits ERM
proteins and the actin cytoskeleton to cell protrusions
(Table 1). This process initiates cellular signalling and
promotes the formation and elongation of microvilli and
filopodia [13], a very important event in cell migration
[65]. It is worth noting that the N-terminal moesin do-
main alone could inhibit endogenous ERM proteins by
competing for the binding of membrane proteins [13].
Previous studies demonstrated that ERM proteins were
essential in the establishment of the bridge between
actin filaments and membrane-associated proteins and
that they were also involved in signal transduction [65].
Activated forms of p-ERM proteins were further found
to translocate from the cytoplasm to the membrane-
cytoskeleton interface [54]. Moesin is a member of the
ERM protein family and serves as a membrane–cytoskel-
eton linker protein [54] (Figure 3).
In addition to the CD146-ERM-actin pathway, the
CD146/ERM complex was found to recruit Rho guanine
nucleotide dissociation inhibitory factor 1 (RhoGDI1,
forming a CD146/moesin/RhoGDI1 heterotrimer), which
Figure 3 An abridged general view of the CD146-ERM-actin and RhoA-PI4P5K-PIP2 signalling pathways is shown. In response to
stimulatory factors, a CD146/moesin/RhoGDI1/PIP2 complex is formed, which activates the RhoA-PI4P5K-PIP2 pathway. This activation induces
PIP2 protein expression and strengthens the anchorage of CD146 to the cytoskeleton, which eventually leads to cell movement.
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its inhibitory interaction with RhoGDI led to both unregu-
lated RhoA activity and enhanced melanoma cell motility
accompanied by remodelling of the cytoskeletal structure
[13,65] (Figure 3). CD146-activated RhoA also acti-
vated the Rho-phosphatidylinositol-4-phosphate-5-kin-
ase-phosphatidylinositol 4,5-biphosphate pathway (i.e.,
RhoA-PI4P5K-PIP2 pathway), which resulted in an in-
crease in the synthesis of PIP2 and its accumulation in the
membrane [13,65]. Lorentzen et al. showed that the bind-
ing of PIP2 to the N-terminal moesin domain was a pre-
requisite for the phosphorylation and activation of ERM
proteins [65]. Luo et al. [13] reasoned that activation of
the RhoA-PI4P5K-PIP2 pathway further reinforced the
phosphorylation and activation of ERM proteins, which
formed a positive feedback loop that enhanced the associ-
ation between the CD146 and ERM proteins (Figure 3).
Rho proteins are members of the Rho family of small
GTPases, and their function correlates with stress fibres
formation. GDIs can inhibit the isolation of GDP from
Rho proteins and GTP hydrolysis, which prevented both
intrinsic GTPase activity and the interactions of Rho pro-
teins with effector molecules.
Recently, Witze et al. [19] described a new model on
the mechanism of cell migration, which explained how
Wnt5a, an extracellular ligand, promoted migration by
the recruitment of CD146; this was required foractomyosin contraction and tailend membrane retrac-
tion (Table 1). When Wnt5a interacted with Frizzled3
(Fz3), a noncanonical Wnt receptor, in WM239A mel-
anoma cells, the Wnt signal was initiated and relayed
by Disheveled-2 (DVL2), which recruited CD146 to
bind. This behavior was revealed by immunoprecipita-
tion, and by the formation of a CD146/DVL2/Fz3 re-
ceptor complex [17,19]. Dvl, a Wnt adaptor protein,
has a PDZ domain that is known to interact directly
with a peptide derived from the KTXXXW motif of Fz3,
which is conserved in all known Fz subtypes [66]. Then,
after internalization through dynamin-mediated endocyto-
sis and Rab4-mediated trafficking of receptor endosomes,
CD146 was transmitted onto the Golgi complex and was
transported by retrograde vesicle to the endoplasmic
reticulum (ER) [19]. This process is partly mediated by
COP-Iβ, and within the Golgi stack, it sorted transmem-
brane proteins that bear C- terminal KKxx or KxKxx
motifs [67].
Further, CD146 was redistributed to the posterior of
the cell and where it functions to assemble actin and
myosinII to form the WRAMP structure, which anchored
to cytoplasmic membrane or to MVBs (multivesicular
bodies) (Figure 4). Formation of the WRAMP structure
was driven in part by adaptor proteins such as IQGAP1,
which bridged the interactions between CD146 and the
cytoskeletal proteins [19]. Finally, the ER was recruited by
Figure 4 A proposed model is that CD146 promotes angiogenesis and mesenchymal cell migration in melanoma. CD146 possibly
induces angiogenesis through the NF-κB p50-IL-6-VEGF signalling pathway. In addition, CD-146 induced IL-6 positively regulates the expression of
Wnt5a. In response to the Wnt5a signal, the CD146/Fz3/DVL2 complex is recruited to the tail end of the cell by means of MVB or ER where it
assembles actin and myosinII filaments to form the WRAMP structure, which directs tail-end membrane retraction.
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posterior, where the WRAMP structure directed tail-
end membrane retraction, and drove the forward
translocation of the cell body. Moreover, directional
movement also required the disassembly of adhesions
in the rear of the cell, which involved the degradation
of focal adhesions and the disassembly of stress fibers
[17,19]. Thus, as a core component of the WRAMP struc-
ture, CD146 was an important role in the migration of
melanoma cells (Figure 4).
Taken together, these studies indicated that these
molecular events that induced cell protrusion, microvilli
and filopodia elongation as well as the rearrangement of
the local cytoskeleton structure resulted in directional
cell movement.
The role of CD146 in the formation of capillary-like
networks and angiogenesis in human melanoma
The progression of neoplasms from benign to malignant
states are often accompanied by the development of an
angiogenic phenotype, as both growth and metastasis
depend upon the ability to generate an adequate vascula-
ture for human melanoma cells.
A number of recent studies have described the angio-
genic role of CD146. Several studies on HUVECs with
CD146 knocked down, by either siRNA or AA98, repor-
ted that these cells could not form a capillary-like tube,
and that the total tube length was lower than the basal
level [12,49,50]. However, the tubular morphogenesis of
the HUVECs was rescued upon restoration of CD146 ex-
pression [50,68]. In addition, several reports demonstrated
that sCD146 enhanced the capacity to establish capillary-like structures in vitro and promoted efficient neovascu-
larisation in vivo in the presence of mCD146 [69,70].
After further research on the structure of CD146,
Kebir et al. [71] found that the two isoforms of CD146,
CD146-l and CD146-s (Figure 1A), displayed distinct
functions: CD146-s appeared to play a major role in the
initial steps of angiogenesis (i.e., migration and prolifera-
tion), whereas, CD146-l was required for the stabilisation
of the capillary-like networks in Matrigel. This finding
suggested that CD146-l was involved in the later stages of
angiogenesis.
To determine the effect of CD146 on tumour angiogen-
esis in human melanoma, Jiang et al. [49] demonstrated
that AA98 or siRNA treatment significantly inhibited
tumour-associated neovascularization, but not in normal
tissues [50]. To elucidate the mechanism of angiogenesis
in human melanoma, a recent report found that overex-
pression of endogenous p50, a member of the NF-κB fam-
ily, significantly enhanced interleukin-6 (IL-6)-induced
endothelial cell growth in vitro and promoted human mel-
anoma angiogenesis in vivo (Figure 4) [72,73]. The latter
study suggested the existence of an NF-κB p50-IL-6-VEGF
signalling axis that stimulated angiogenesis in human mel-
anoma (Figure 4, Table 1).
The identification of five analogous characteristics
between CD146 and p50 in human melanoma suggested
that CD146 correlated strongly with p50 and, contributed
to the acquisition of an angiogenic phenotype which was
induced by the NF-κB p50-IL-6-VEGF signaling axis.
These five characteristics are as follows: (1) According
to one study, in melanoma, p50 [72] and CD146 [39]
were similarly overexpressed in dysplastic nevi and
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sion in normal nevi and healthy melanocytes, respectively;
(2) p50 expression had no significant effect on growth rate
of melanoma cell in vitro [72], and these data agreed with
the known role of CD146 [41,45]; (3) HUVECs transfected
with CD146/C452A, which did not allow for the for-
mation of dimers, did not form capillary-like tubes in
response to VEGF in one study [74], which suggested that
CD146 dimerisation played a crucial role in the patho-
logical angiogenesis stimulated by VEGF. With human
melanoma-conditioned medium, CD146 dimerisation was
induced by the NF-κB pathway and was down-regulated
by mAb AA98 [75]. These results implied that CD146
dimerisation was required for the p50-induced VEGF-
mediated formation of new blood vessels. (4) Both p50
[72] and CD146 exerted identical effects on angiogenesis
both in vitro and in vivo. (5) Some of the latest reports
showed that CD146 was positively correlated with VEGF
-induced NF-κB activation in the endothelium [50,68].
Although these results provide strong evidence that
supports our hypothesis, the specific interactions be-
tween CD146 and p50 in human melanoma cells remain
nuclear. There may be two pathways that regulate angio-
genesis in melanoma. In addition to the VEGF-CD146-
NF-κB pathway that is present in the endothelium, the
CD146-NF-κB p50-IL-6-VEGF pathway probably repre-
sents another mechanism that exists in melanoma cells
that interacts with the endothelium via paracrine secre-
tion. This notion was supported by a recent report that
tumour endothelial cells from human bone sarcomas
which lack VEGF expression still demonstrated the cap-
ability for high proliferation and for the development of
capillary-like structures and colony formation units [76].
Besides, these results also verified the validity of our
hypothesis in that after MSCs were co-cultured with
A375 cells, the expression levels of VEGF-2 and CD146
were both increased in MSCs [77].
Moreover, the signal transduction cascade could also
partly explain the role of CD146 in IL-6-induced inflam-
mation if it actually occurred. Given that IL-6 positively
regulated the Wnt5a expression through the p38α-MAPK
pathway in melanoma [78], we draw the reasonable infer-
ence that CD146 probably drives melanoma cell motility
through the CD146-IL-6-p38α-MAPK- Wnt5a-WRAMP
pathway (Figure 4). In addition, the role of CD146 dimers
compared with the CD146 monomer in tumour angiogen-
esis requires clarification; and the determination whether
CD146 or NF-κB p50 is the initiating factor needs to be
addressed. Ongoing work in our laboratory that involves
immunoprecipitation, immunoblotting, and CD146 silen-
cing both in vitro and in vivo aims to address these issues.
Both host vascular endothelial cells and melanoma cells
express CD146. The currently available anti-angiogenic
agents have been developed based upon a non-specific,general understanding of angiogenesis rather than a
specific tumour-associated characterization. As tumour-
specific angiogenesis may differ from general understanding,
novel anti-angiogenic agents that target tumour-derived
endothelial cells rather than normal endothelium are
urgently needed. The anti-CD146 AA98 mAb may be of
use with respect to anti-angiogenesis, as AA98 has shown
remarkably restricted immunoreactivity against the tumour
vasculature compared with blood vessels of normal tissues
[49]. Thus, the targeting of CD146 by AA98, or another
CD146 inhibitor, siRNA or vaccine, could significantly
inhibit both the growth and metastasis of melanoma
[39,49,50].Conclusions and future perspectives
Melanoma is a life-threatening skin cancer that is increas-
ingly diagnosed throughout the world. To enable better
treatment, early detection and prognostic markers are ne-
cessary. CD146, as a suitable marker of poor patient out-
come [79], has already been used as an additional tool for
the distinction for tumour progression beyond melanoma
[80,81]. Based on this theory, a novel immunosensor has
been devised to detect CD146 with a high sensitivity,
which has achieved a satisfactory result [82].
In this review, we have suggested that CD146 acts as
the primary mediator of multiple characteristics of mel-
anoma cells (Table 1). More importantly, we delineated
the different cell signalling mechanism induced by
CD146 that corresponded to the different biological
properties of melanoma. The work collectively indicates
that therapeutic agents that target CD146 or these sig-
nalling pathways could provide greater specificity, less
toxicity, and higher therapeutic indices than the cur-
rently available therapeutics. These targets might also
represent a novel therapeutic avenue in the treatment of
human melanoma. Well-designed clinical trials are ne-
cessary to ensure the effectiveness of these proposed
inhibitors.
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